Literature DB >> 23295923

Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.

Noton K Dutta1, Abdullah Alsultan, Charles A Peloquin, Petros C Karakousis.   

Abstract

Substitution of rifapentine (RFP) for rifampin (RIF) in the standard antituberculous regimen reduces the time required to cure chronic tuberculosis (TB) infection in mice, but not in guinea pigs. In order to gain insight into these discrepant findings, we conducted a steady-state pharmacokinetic (PK) study in healthy guinea pigs to study the metabolism and autoinduction of RIF and RFP. Both RFP and RIF 25-desacetyl metabolites (desRFP and desRIF, respectively), were detected at low concentrations in the serum of guinea pigs. The metabolite concentrations in guinea pigs are much lower than those seen in humans at steady state.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295923      PMCID: PMC3591898          DOI: 10.1128/AAC.01933-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  J Antimicrob Chemother       Date:  2000-10       Impact factor: 5.790

3.  Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.

Authors:  K E Dooley; E E Bliven-Sizemore; M Weiner; Y Lu; E L Nuermberger; W C Hubbard; E J Fuchs; M T Melia; W J Burman; S E Dorman
Journal:  Clin Pharmacol Ther       Date:  2012-05       Impact factor: 6.875

4.  Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Authors:  Noton K Dutta; Peter B Illei; Charles A Peloquin; Michael L Pinn; Khisimuzi E Mdluli; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

5.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

6.  Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Authors:  Rovina Ruslami; Hanneke M J Nijland; Bachti Alisjahbana; Ida Parwati; Reinout van Crevel; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

7.  Disposition and metabolism of 14C-rifapentine in healthy volunteers.

Authors:  K Reith; A Keung; P C Toren; L Cheng; M G Eller; S J Weir
Journal:  Drug Metab Dispos       Date:  1998-08       Impact factor: 3.922

8.  Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.

Authors:  Marc Weiner; Naomi Bock; Charles A Peloquin; William J Burman; Awal Khan; Andrew Vernon; Zhen Zhao; Stephen Weis; Timothy R Sterling; Katherine Hayden; Stefan Goldberg
Journal:  Am J Respir Crit Care Med       Date:  2004-02-12       Impact factor: 21.405

9.  Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

Authors:  C A Peloquin; R Namdar; M D Singleton; D E Nix
Journal:  Chest       Date:  1999-01       Impact factor: 9.410

10.  Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Authors:  Susan E Dorman; Stefan Goldberg; Jason E Stout; Grace Muzanyi; John L Johnson; Marc Weiner; Lorna Bozeman; Charles M Heilig; Pei-Jean Feng; Ruth Moro; Masahiro Narita; Payam Nahid; Susan Ray; Edward Bates; Betial Haile; Eric L Nuermberger; Andrew Vernon; Neil W Schluger
Journal:  J Infect Dis       Date:  2012-07-30       Impact factor: 5.226

View more
  6 in total

1.  Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen.

Authors:  Noton K Dutta; Rongjun He; Michael L Pinn; Yantao He; Francis Burrows; Zhong-Yin Zhang; Petros C Karakousis
Journal:  ACS Infect Dis       Date:  2015-12-24       Impact factor: 5.084

2.  Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

3.  Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis.

Authors:  Xiuhao Chen; Hiroyuki Hashizume; Tatsuo Tomishige; Izuru Nakamura; Miki Matsuba; Mamoru Fujiwara; Ryuki Kitamoto; Erina Hanaki; Yoshio Ohba; Makoto Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Authors:  Laura E Via; Rada Savic; Danielle M Weiner; Matthew D Zimmerman; Brendan Prideaux; Scott M Irwin; Eddie Lyon; Paul O'Brien; Pooja Gopal; Seokyong Eum; Myungsun Lee; Jean-Philippe Lanoix; Noton K Dutta; TaeSun Shim; Jeong Su Cho; Wooshik Kim; Petros C Karakousis; Anne Lenaerts; Eric Nuermberger; Clifton E Barry; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2015-05-08       Impact factor: 5.084

5.  Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.

Authors:  Noton K Dutta; Abdullah Alsultan; Thomas J Gniadek; Deborah A Belchis; Michael L Pinn; Khisimuzi E Mdluli; Eric L Nuermberger; Charles A Peloquin; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

6.  Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?

Authors:  Noton K Dutta; Petros C Karakousis
Journal:  Front Microbiol       Date:  2015-10-14       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.